Ligand Screening for E3 Ligase
CD ComputaBio is a leading provider of computational biology services, specializing in ligand screening for E3 ligase. Our team of experienced scientists and cutting-edge technology allow us to deliver high-quality results to our clients in the pharmaceutical and biotechnology industries.
Introduction of Ligand Screening for E3 Ligase
E3 ligases are essential components of the ubiquitin-proteasome system, a crucial cellular pathway for protein degradation. They play a critical role in regulating various cellular processes, including cell cycle control, signal transduction, and DNA repair. Dysregulation of E3 ligases has been implicated in the development and progression of numerous diseases, making them attractive targets for drug discovery. By screening libraries of compounds, researchers can identify potential drug candidates that can selectively bind to and modulate the activity of specific E3 ligases.
Figure 1. Ligand Screening for E3 Ligase. (Johansson H, et al.2019)
Our Service
Virtual screening
We use state-of-the-art computational methods to screen libraries of small molecules and identify potential drug candidates that can bind to and modulate the activity of E3 ligases.
Molecular docking
We use molecular docking simulations to predict the binding affinity and binding mode of small molecules to E3 ligases, allowing us to prioritize potential drug candidates for further study.
Pharmacophore modeling
We use pharmacophore modeling to identify key structural features that are essential for the binding of small molecules to E3 ligases, helping us design novel drug candidates with improved potency and selectivity.
Quantitative Structure-Activity Relationship (QSAR) Modelling
Predictive models can be developed to understand the relationship between the chemical structure of a ligand and its biological activity against E3 ligases.
The process of Ligand Screening for E3 Ligase
Project Consultation - Understanding the specific requirements and objectives of our clients.
Computational Analysis - Employing a combination of virtual screening, molecular modeling, and simulation techniques.
Hit Identification - Identifying potential ligands with the desired binding properties.
Hit Validation - Performing in-depth analyses to validate the efficacy and specificity of selected ligands.
Report Generation - Delivering comprehensive reports with detailed findings and recommendations for further experimental validation.
Approach to Ligand Screening for E3 Ligase
Structure-based drug design
We use the three-dimensional structure of the target E3 ligase to design novel drug candidates with improved potency and selectivity.
Ligand-based drug design
We use the chemical and structural properties of known ligands to design novel drug candidates that can selectively bind to and modulate the activity of the target E3 ligase.
Fragment-based drug design
We use fragment-based screening approaches to identify small molecules that can bind to the target E3 ligase and serve as starting points for drug discovery.
Advantages of Our Services
Precision
By leveraging advanced algorithms and modeling techniques, we identify ligands with high binding affinity and selectivity for E3 ligases.
Cost-Effectiveness
Our services offer a cost-effective alternative to traditional experimental screening methods, minimizing experimental errors and redundancies.
Customization
We tailor our services to meet the specific needs and objectives of each client, providing personalized solutions for diverse drug discovery projects.
Ligand screening for E3 ligase is a crucial step in drug discovery efforts targeting these important enzymes. At CD ComputaBio, we offer comprehensive ligand screening services for E3 ligase to support our clients in the pharmaceutical and biotechnology industries. Our team of experts, cutting-edge technology, and customized solutions make us the ideal partner for your ligand screening needs. Contact us today to learn more about our services and how we can help you accelerate your drug discovery efforts.
References:
- Kohlbacher S M, Langer T, Seidel T. QPHAR: Quantitative pharmacophore activity relationship: Method and validation. Journal of cheminformatics, 2021, 13: 1-14.
- Alamri M A. Pharmacoinformatics and molecular dynamic simulation studies to identify potential small-molecule inhibitors of WNK-SPAK/OSR1 signaling that mimic the RFQV motifs of WNK kinases[J]. Arabian Journal of Chemistry, 2020, 13(4): 5107-5117.
- Johansson H, Isabella Tsai Y C, Fantom K, et al. Fragment-based covalent ligand screening enables rapid discovery of inhibitors for the RBR E3 ubiquitin ligase HOIP[J]. Journal of the American Chemical Society, 2019, 141(6): 2703-2712.
* For Research Use Only.
Related Services
